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Abstract Described here is the unusual case of a previ-
ously healthy 17-month-old girl who developed severe
cytomegalovirus (CMV) disease with prolonged fever and
hepatitis. The severity of her illness required hospitaliza-
tion and prompted antiviral treatment. Short-term intra-
venous ganciclovir treatment was associated with imme-
diate and sustained resolution of the symptoms as well as
a sharp decrease of CMV viremia. This observation
suggests that antiviral therapy might be considered in
select cases of severe primary CMV infection in immu-
nocompetent children.
Introduction
Primary cytomegalovirus (CMV) infection in immuno-
competent children is generally a self-limited condition
that does not require antiviral therapy [1]. We report here
the unusual case of a breast-fed child with CMV whose
infection was so severe that ganciclovir treatment was
required. We also performed a literature review to collect
evidence supporting the use of ganciclovir treatment in
immunocompetent children.
Case Report
A previously healthy 17-month-old girl was referred to our
institution with a 4-week history of persistent fever. She had been
born to a healthy mother at 38 weeks’ gestation (birth weight,
2,940 g) and was still being breast-fed. At the age of 13 months, she
started attending a day-care center. Three months later she was
admitted to a nearby hospital with high-grade fever, a runny nose
and acute bronchitis that persisted despite 8 days of antibiotic
treatment.
Remarkable findings on clinical examination included fever
(39C), a truncal macular erythematous rash, cervical lym-
phadenopathies and splenomegaly. Laboratory tests showed ane-
mia, leukocytosis (18.9 g/l; normal range, 4–11) with absolute
lymphocytosis (12.6 g/l; normal range, 3–9.5), a moderate inflam-
matory state (C-reactive protein, 21 mg/l) and a slight elevation of
aspartate aminotransferase levels (67 U/l; normal range, 11–42).
Repeated blood, urine and stool cultures for bacteria and/or virus
identification were all negative. Serological tests to detect hepatitis
A, B and C, HIV, adenovirus, Toxoplasma gondii, Brucella spp.
and Borrelia burgdorferi were all negative. Immunoglobulin (Ig)G
but not IgM antibodies against HHV-6, parvovirus B19 and
Epstein-Barr virus were detected, and post-vaccination serological
tests for rubella and measles were positive. IgG and IgM antibodies
against CMV were not detected. Tests for P24 antigenemia and
Epstein-Barr virus DNA were also negative. Antigen detection
(ELISA) for respiratory syncytial virus, influenza, parainfluenza
and adenovirus on nasopharyngeal secretions were negative. Chest
radiograph was within the normal limits and abdominal ultraso-
nography confirmed the splenomegaly.
Atypical Kawasaki disease was suspected, and the infant was
given intravenous immunoglobulins (2 g/kg) and aspirin (80 mg/
kg). Fever decreased partially and 10 days after admission the
patient was released. High-grade fever rapidly relapsed, and she
was referred to our hospital for further examination.
At admission, her general condition was poor; the results of the
physical examination were unchanged, but liver enzymes had
worsened, with elevated aspartate aminotransferase, alanine ami-
notransferase and GGT levels of 228 U/l (normal range, 14–50),
291 U/l (normal range, 9–42) and 370 U/l (normal range, 9–35),
respectively. A liver biopsy showed a lymphohistiocytic infiltrate
predominant in the portal tracts, non-caseating epithelioid cell
granuloma in the lobules, and early-antigen immunostaining was
positive for nuclear CMV in hepatocytes (Fig. 1). At this time,
CMV pp65 antigenemia was revealed in blood leukocytes (44
positive cells/250,000 leukocytes) as was CMV DNA in plasma
(3,535 copies/ml) and CMV early-antigen in urine by rapid culture.
These findings prompted the diagnosis of severe primary CMV
disease with associated hepatitis.
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Given the poor condition of the patient and the prolonged
duration of symptoms, intravenous ganciclovir was introduced for 5
days (5 mg/kg b.i.d.) together with nonspecific immunoglobulin for
2 days (1 g/kg/d). Within 36 h we observed a dramatic resolution of
the clinical symptoms and the fever, and 5 days later the child was
discharged without further treatment (Fig. 2). Four days after the
initiation of ganciclovir, pp65 antigenemia and CMV DNAemia
decreased sharply to 1 positive cell/250,000 leukocytes and
185 copies/ml, respectively. At 1-month follow-up, aspartate ami-
notransferase and alanine aminotransferase levels were still mod-
erately elevated at 145 and 160 U/l, respectively, GGT levels were
normalized, and pp65 antigenemia and CMV DNAemia were
negative.
Testing of the mother revealed her to be IgG-positive for CMV.
Breast milk sampled at the time of hospitalization tested positive
for CMV early-antigen but plasma was negative for CMV DNA.
Discussion
This severe case of primary CMV disease in an immu-
nocompetent 17-month-old girl resolved with ganciclovir
treatment. An unusual aspect of the case is that the child
had never presented previously with a disease suggestive
of an immunodeficiency. In contrast with perinatal CMV
infection, which can be a severe disease [2, 3, 4, 5], CMV
infection later in life is generally asymptomatic in
immunocompetent children and adults. In rare cases, a
self-limited mononucleosis-like syndrome with mild liv-
er-test abnormalities can be present. Severe and pro-
longed disease over months and years in immunocompe-
tent hosts is very uncommon but does exist.
In an extensive review of the medical literature, we
found descriptions of 34 cases of severe CMV disease in
immunocompetent adults [6] and only six cases in
immunocompetent children [5, 7]. Of these six children,
five were aged 1–5 years and one was aged 8 months. All
of them presented with CMV hepatitis that lasted for
weeks or months; one case resulted in death. Our patient
presented with severe and prolonged disease with proven
CMV hepatitis and required hospitalization. Congenital
immune dysfunction was not documented and was very
unlikely in the absence of previous infections and
laboratory abnormalities. Due to the recently adminis-
tered intravenous immunoglobulin perfusion, we could
not accurately quantify the different immunoglobulin
classes.
Since primary CMV infection in immunocompetent
hosts is generally self-limited, no specific antiviral
therapy is usually required. However, antiviral therapy
can be beneficial in immunocompetent hosts, including
adults, with severe acute or persistent CMV infection, as
reported in a limited number of cases [3, 5, 6]. For
example, nine immunocompetent infants and children
aged 20 days to 33 months each received a 2-week-course
of intravenous ganciclovir (n=6) in association with anti-
CMV immunoglobulin (n=2) or anti-CMV immunoglob-
ulin alone (n=1) for severe CMV disease [3, 5]. Isolated
or combined ganciclovir treatment was effective in
resolving either hepatitis or CMV-related symptoms in
these patients.
In our patient, the symptoms and duration of the
primary CMV infection were severe enough for antiviral
therapy to be considered, with fever persisting for more
than 4 weeks after symptom onset. However, in contrast
with the prolonged course of ganciclovir reported in the
previous cases, the treatment administered to our patient
was limited to 5 days, which proved effective in resolving
fever and hepatitis and correlated with a dramatic
decrease of viremia. This was confirmed by the absence
of clinical relapse and the negative CMV DNAemia result
obtained 1 month later.
Fig. 1 Non-caseating epitheloid cell granuloma in a hepatic lobule
characteristic of CMV hepatitis in an immunocompetent host
(hematoxylin and eosin staining); focally positive nuclear early-
antigen immunostaining in a hepatocyte (inset)
Fig. 2 Schematic presentation of the clinical and biological evo-
lution of CMV infection in a 17-month-old patient treated with
ganciclovir
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It is worth noting that oral valganciclovir is now
available and might be an alternative to intravenous
therapy, although no post-licensing data are actually
available for infants. It must be kept in mind, however,
that the large majority of cases do not require treatment
and the bone marrow and gonadal toxicities associated
with ganciclovir must be taken into account. Kimberlin et
al. [8] reported that almost two-thirds of ganciclovir-
treated infants with congenital CMV disease involving the
central nervous system had significant neutropenia. In this
respect, foscanavir, which has less gonadal toxicities,
might be an alternative for treatment. Thus, ganciclovir
treatment of immunocompetent children should be re-
served for highly selected cases only.
Breast-feeding (vertical transmission) and day-care-
center attendance (horizontal transmission) are the two
major sources of postnatal CMV acquisition [1]. Local-
ized reactivation and intermittent excretion of CMV in the
breast milk of postpartum IgG-positive women are
common and can last for up to 6 months [9, 10, 11].
CMV virions have been detected by culture in the breast
milk of 32% to 50% of IgG-positive women [1, 10, 11,
12]. The rate of mother-to-child transmission averages
30% to 40%, and the risk is higher when the duration of
breast-feeding is longer [1, 11]. CMV infection of the
infant usually ensues between birth and 8 months of age
and is generally self-limited, except in preterm and low-
birth-weight neonates [4, 11, 13]. Day-care-center atten-
dance is the other important means by which children
acquire postnatal CMV infection [14]. Chronic shedding
of high quantities of CMV into saliva and urine facilitates
horizontal transmission between toddlers aged 1–3 years
but, as with vertical transmission, the subsequent CMV
infection is generally subclinical [1, 14].
In the case presented here, we considered vertical
transmission to be the likely source of CMV transmission
since CMV culture of the mother’s breast milk was
positive concomitant to the child’s severe CMV disease.
However, since molecular identity testing was not per-
formed to compare the CMV strains obtained from the
child and the mother’s breast milk, this hypothesis cannot
be definitely confirmed. In addition, CMV transmission
by breast-feeding so late in life is unusual and we did not
find any similar reports in the current literature. Another
likely source of CMV acquisition in our patient could be
horizontal transmission via the saliva of an infected child
attending the same day-care center.
The case presented here shows that primary CMV
infection can lead to severe and prolonged disease, not
only in neonates and high-risk infants, but in immuno-
competent older children as well. Our observation sug-
gests that antiviral therapy can shorten the duration of
disease and might be considered in selected cases.
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